Showing results (271-280 of 308) with videos related to
Sort By:
Pageof 31
Contemporary Clinical Trials|May 31, 2024
Functional outcomes of diets in multiple sclerosis (FOOD for MS): Protocol for a parallel arm randomized feeding trial for low glycemic load and calorie restrictionKat Martin, Stacey S Cofield, Anne H Cross, et al.Plos One|September 1, 2010
Ezrin is highly expressed in early thymocytes, but dispensable for T cell development in miceMeredith H Shaffer, Yanping Huang, Evann Corbo, et al.Neurology|November 14, 2024
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic IndicationsCarson M Quinn, Prashanth Rajarajan, Alexander J Gill, et al.The New England Journal of Medicine|August 24, 2022
Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisLawrence Steinman, Edward Fox, Hans-Peter Hartung, et al.Neurology. Clinical Practice|January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MSAndrew Chan, John Rose, Enrique Alvarez, et al.Journal of Neuroimmunology|September 4, 2023
SARS-CoV-2 mRNA vaccination induces an antigen-specific T cell response correlating with plasma interferon-gamma in B cell depleted patientsTyler L Borko, Ryan Baxter, Berenice Cabrera-Martinez, et al.Science Translational Medicine|July 20, 2022
Miswiring of Merkel cell and pruriceptive C fiber drives the itch-scratch cycleJing Feng, Yonghui Zhao, Zili Xie, et al.Annals of Clinical and Translational Neurology|February 22, 2023
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosisBritney Barrera, Haley Simpson, Eric Engebretson, et al.JAMA Oncology|September 1, 2022
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity SyndromeOmar H Butt, Alice Y Zhou, Paolo F Caimi, et al.Multiple Sclerosis and Related Disorders|June 25, 2023
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trialMitzi J Williams, Annette F Okai, Anne H Cross, et al.Pageof 31